Ronan Martin Murphy Sells 841 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) Director Ronan Martin Murphy sold 841 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $138,167.89. Following the transaction, the director directly owned 3,847 shares of the company’s stock, valued at approximately $632,023.63. This trade represents a 17.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Up 0.2%

ICLR opened at $167.48 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. Icon Plc has a 12 month low of $66.57 and a 12 month high of $203.91. The stock has a market capitalization of $12.82 billion, a P/E ratio of 39.31, a P/E/G ratio of 6.93 and a beta of 1.21. The business has a 50 day simple moving average of $162.22 and a 200-day simple moving average of $134.04.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.Icon’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.26 earnings per share. On average, equities analysts anticipate that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue of $2.06 billion topped estimates of $2.00 billion. Revenue also rose 2.3% year over year, indicating continued demand for its outsourced clinical-research services.
• Positive Sentiment: Analyst support remains a potential catalyst. BMO Capital Markets raised its price target to $187, Mizuho lifted its target to $190, and William Blair upgraded the stock to “strong buy.” The broader analyst consensus is “Hold,” with an average target of $170.40. Analyst coverage article
• Positive Sentiment: Institutional ownership is high at 95.61%, and several investment firms recently initiated or increased positions in ICLR. The stock is also trading above its 50-day and 200-day moving averages, reflecting favorable recent momentum.
• Neutral Sentiment: CEO Barry Balfe, CFO Nigel Clerkin and several directors sold shares totaling roughly $1.6 million at prices near $164.07–$164.29. The filings state that the sales were made to cover tax-withholding obligations connected with vested equity awards, and the insiders retained shares afterward, reducing the negative signal. Icon insider sales article
• Negative Sentiment: Although revenue beat estimates, quarterly EPS fell from $3.26 in the prior-year period, highlighting earnings pressure. ICLR also trades at a relatively demanding valuation, with a price-to-earnings ratio near 39 and a PEG ratio above 6, leaving the stock vulnerable if growth or guidance weakens.

Hedge Funds Weigh In On Icon

Hedge funds have recently added to or reduced their stakes in the business. EFG International AG acquired a new position in Icon during the fourth quarter worth about $27,000. Abound Financial LLC acquired a new stake in shares of Icon in the fourth quarter valued at approximately $54,000. GAMMA Investing LLC grew its position in shares of Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after purchasing an additional 69 shares during the last quarter. Johnson Financial Group Inc. purchased a new position in shares of Icon during the 3rd quarter worth approximately $71,000. Finally, Blue Trust Inc. raised its position in shares of Icon by 207.5% during the 1st quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after purchasing an additional 444 shares during the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ICLR. Citigroup increased their price target on shares of Icon from $165.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Weiss Ratings lowered shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Robert W. Baird set a $194.00 target price on shares of Icon in a report on Friday, July 31st. Bank of America lifted their price target on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research report on Thursday, June 25th. Finally, JPMorgan Chase & Co. boosted their price target on Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $170.40.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.